argenx NV ADR (ARGX)vsCompugen (CGEN)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
CGEN
Compugen
$2.07
-0.96%
HEALTHCARE · Cap: $198.49M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 5722% more annual revenue ($4.24B vs $72.76M). CGEN leads profitability with a 48.6% profit margin vs 30.5%. ARGX appears more attractively valued with a PEG of 0.83. CGEN earns a higher WallStSmart Score of 71/100 (B).
ARGX
Buy63
out of 100
Grade: C+
CGEN
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+33.7%
Fair Value
$2.58
Current Price
$2.07
$0.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Attractively priced relative to earnings
Every $100 of equity generates 45 in profit
Keeps 49 of every $100 in revenue as profit
Strong operational efficiency at 83.2%
Revenue surging 44.8% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : CGEN
The strongest argument for CGEN centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 48.6% and operating margin at 83.2%. Revenue growth of 44.8% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : CGEN
The primary concerns for CGEN are EPS Growth, Market Cap.
Key Dynamics to Monitor
CGEN carries more volatility with a beta of 2.96 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CGEN scores higher overall (71/100 vs 63/100), backed by strong 48.6% margins and 44.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compugen
HEALTHCARE · BIOTECHNOLOGY · USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?